Bristol-myers Squibb Pharma Company

Other

Spectrum Pharmaceuticals, Inc.

John A Barrett

Milind Rajopadhye

Alan P Carpenter, Jr

Thomas David Harris

Shuang Liu

Edward H Cheesman

Michael Sworin

D Scott Edwards

Prahlad R Singh

Stuart J Heminway

Jingwu Duan

Carl P Decicco

David J Nelson

Sribalaji Lakshmikanthan

Stuart D Heminway

Singh R Prahlad

Alan P Carpenter Jr

This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer at a fixed dose regardless of the patient's weight.

Methods of treating chemotherapy induced neutropenia using fixed doses of eflapegrastim

The present invention describes novel compounds of the formula:(Q)&#x2014;L&#x2014;C,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Vitronectin receptor antagonist pharmaceuticals

The present invention describes novel compounds of the formula:(Q)-L-C,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

The present invention describes novel compounds of the formula:(Q)&#x2014;L&#x2014;C,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Pharmaceuticals for the imaging of angiogenic disorders

The present invention describes novel compounds of the formula:(Q)&#x2014;L&#x2014;C,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Thus the present invention describes novel compounds comprising 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits and their uses in treatment of diseases associated with MMPs.

Matrix metalloproteinase inhibitors

The present invention provides novel radiopharmaceuticals useful for the diagnosis of infection and inflammation, reagents and kits useful for preparing the radiopharmaceuticals, methods of imaging sites of infection and/or inflammation in a patient, and methods of diagnosing diseases associated with infection or inflammation in patients in need of such diagnosis. The radiopharmaceuticals bind in vivo to the leukotriene B4 (LTB4) receptor on the surface of leukocytes which accumulate at the site of infection and inflammation. The reagents provided by this invention are also useful for the treatment of diseases associated with infection and inflammation.

Radiopharmaceuticals for imaging infection and inflammation

An electrical generator for mounting on a railroad car axle end which utilizes the rotation of the axle to generate electricity. The generator includes a housing assembly bolted to the end of a railroad car axle, preferably using the bolt holes that are present on conventional axle ends. The housing includes a tubular rim along which is mounted a plurality of spaced permanent magnets. A stator fastened to a stationary part of the car, typically the outer race of the axle bearing, mounts a plurality of coils in a circular array, closely spaced to the magnets. Electricity is generated whenever the car axle is rotating.

Railroad car with axle-mounted electrical generator

This invention relates to methods, devices and systems for exercise. An embodiment of this invention comprises a circular exercise wheel in the shape of a conventional automobile steering wheel with a weight attached along its diameter with a pair of wing nuts. The wing-nuts and bolts are attached such that they cannot be lost or stolen or misplaced.

Growing community of inventors

Groton, MA, United States of America

John A Barrett